LVIVSKYI NATIONALNYI MEDYCHNYI UNIVERSYTET IMENI DANYLA HALYTSKOHO

Their core work

Danylo Halytsky Lviv National Medical University is a Ukrainian higher education and research institution whose scientific work sits at the intersection of immunology, inflammation biology, and oncology. Their researchers study how immune cells — particularly neutrophils — behave in disease states such as autoimmune conditions and cancer, and how reactive oxygen species (ROS) can be selectively amplified or targeted for therapeutic effect. In the NeutroCure project, they are contributing to the development of "smart" ROS amplifiers that specifically target aberrant polymorphonuclear neutrophils implicated in inflammatory and autoimmune pathology. Earlier participation in the PANG project placed them at the intersection of microbiology and materials science, examining how pathogens interact with graphene-based structures.

What they specialise in

How they've shifted over time

In their first H2020 engagement (PANG, 2016–2019), the university contributed to research on pathogen-graphene interactions — a topic that sits at the boundary of microbiology and advanced materials, with no overlap in recorded keywords with their later work. By 2020, their focus shifted decisively toward clinical immunology: reactive oxygen species, neutrophil dysfunction, autoimmunity, inflammation, and cancer — all keywords from NeutroCure. This trajectory suggests a move from exploratory materials-meets-microbiology research toward translational, disease-targeted immunology with clearer therapeutic applications.

The university is moving toward translational immunology — specifically the therapeutic manipulation of neutrophil behavior via reactive oxygen species — which positions them as a potential partner for projects targeting autoimmune diseases, chronic inflammation, or cancer immunotherapy.

How they like to work

This university has participated exclusively as a consortium partner, never as coordinator, across both H2020 projects. With 18 distinct partners spread across 7 countries in just two projects, they engage in relatively broad, internationally diverse consortia rather than repeating partnerships with the same institutions. Their participation in an MSCA-RISE project indicates they contribute specific scientific expertise through staff exchange and mobility arrangements, suggesting they function best as a focused specialist node rather than a project driver.

The university has built connections with 18 unique consortium partners across 7 countries through only two projects, indicating dense but geographically distributed networks. Their collaboration footprint spans European partners typical of both MSCA-RISE mobility schemes and RIA research consortia.

What sets them apart

As a Ukrainian medical university, Danylo Halytsky Lviv National Medical University brings a distinct Eastern European clinical research perspective that is relatively rare in H2020 consortia — particularly valuable for projects seeking geographic diversity or access to patient cohorts in Ukraine. Their specific combination of expertise in neutrophil biology, ROS-based targeting, and autoimmunity fills a niche that sits between basic immunology and therapeutic development. For consortium builders in inflammation or cancer immunotherapy, they offer both specialist biomedical knowledge and the practical advantage of a clinical academic environment with potential for translational follow-through.

Highlights from their portfolio

• NeutroCure
  The largest project by funding (EUR 184,352) and the most scientifically specific: developing smart ROS amplifiers targeting aberrant neutrophils in autoimmune disease and cancer — a highly focused translational immunology effort running through 2025.
• PANG
  An earlier MSCA-RISE mobility project linking pathogen biology with graphene materials science, demonstrating the university's willingness to participate in interdisciplinary, cross-sector consortia beyond their core clinical immunology focus.